Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » Bayer, CRISPR Therapeutics Launch JV to Develop CRISPR/Cas9 Treatments

Bayer, CRISPR Therapeutics Launch JV to Develop CRISPR/Cas9 Treatments

Dec 21, 2015
|
staff reporter

NEW YORK (GenomeWeb) – Switzerland's CRISPR Therapeutics and Germany's Bayer today announced a yet unnamed joint venture to develop ways to deliver CRISPR/Cas9 genome editing in a clinical setting.

The deal brings together Bayer's experience in protein engineering and knowledge of human diseases with CRISPR Therapeutics' CRISPR/Cas9 intellectual property and genome editing expertise, the firms said in a statement.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Russia Vaccine Approval Raises Concerns

The Wall Street Journal reports that Russia's announcement of a coronavirus vaccine approval was met with concern as safety testing has not yet been completed.

Numbers Needed

New Scientist writes there aren't much data available on the accuracy of the two rapid COVID-19 tests the UK plans to roll out.

PNAS Papers on Sarcoma Fusion Effects, Transfer RNA Changes in Colon Cancer, TB-T2D Interactions

In PNAS this week: downstream effect of oncoprotein fusion, epigenetic changes influence tRNAs in colon cancer, and more.

Move Away From Basic Research?

Nature News reports that recent proposed changes to the US National Science Foundation have raised concerns about a shift away from the agency's focus on basic research.

What's Popular?

In Business News

  1. Illumina Q2 Revenues Drop 25 Percent

  2. Blackstone to Acquire Ancestry for $4.7B

  3. HTG Molecular Diagnostics, Qiagen Ink CDx Commercialization, Distribution Agreement

  4. Rakuten Medical Sues Illumina Over Trademark Dispute

  5. Adaptive Biotechnologies Q2 Revenues Fall 5 Percent, Beat Analyst Estimates

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.